Previously, we conducted the Aldose Reductase Inhibitor-Diabetes Complications Trial, a 3-year multicentre comparative clinical trial of conventional therapy (control group) and epalrestat, an aldose reductase inhibitor, with conventional therapy (epalrestat group) in Japanese patients with mild diabetic neuropathy. This evidence concerns the gene AKR1B1 and diabetes mellitus.